2 Healthcare Stocks That Doubled in 2019 and Can Still Go Higher

Investing in healthcare can be an excellent way for investors to diversify their portfolios and take a position in strong, stable markets that will continue to see demand for the foreseeable future. The two stocks listed below not only have a lot of long-term potential but have already delivered strong results this year with both of their share prices doubling, dwarfing the S&P 500’s returns of 29% in 2019…

1. Seattle Genetics

Seattle Genetics (NASDAQ:SGEN) was having a good year in 2019 with the stock up around 30% in September. Things really started to take off for Seattle Genetics when the company released results of its phase 1 clinical trial for EV-103, which is designed to treat patients with urothelial cancer, the most common type of bladder cancer. The company announced that “the study met outcome measures for safety and exhibited encouraging clinical activity for this platinum-free combination in a first-line setting.” It’s a good first step for the drug, but phase 1 is still very early on in a drug’s testing and it is no guarantee that EV-103 will hit the market anytime soon. It could still be years before all the necessary testing is complete.

The company got another boost in its share price in October when it announced positive results from a trial evaluating its tucatinib drug in treating patients with HER2-positive breast cancer. The drug was used with trastuzumab and capecitabine and showed encouraging results, so much so that the company announced it would submit a new drug application in early 2020.

On Oct. 29 the company released its third-quarter results for 2019, which showed strong year-over-year sales growth of 26%. And although losses rose from $67.4 million last year to $91.9 million in Q3, given the company’s progress in its drug trials in recent months, it’s easy to see why investors haven’t been discouraged by the results.

There’s a lot of potential for Seattle Genetics to rise even higher if the company continues to see progress from the development of its drugs.

2. Insulet

Insulet‘s (NASDAQ:PODD) stock has fallen in December, but the stock has still had an impressive year in 2019…

Continue reading at THE MOTLEY FOOL

Leave a Reply

Your email address will not be published. Required fields are marked *